Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Multi-center, Single-dose, Randomized, Double-blind, Non-inferiority and Lot-to-lot Consistency Study of Immunogenicity and Safety Evaluation of AdimFlu-S Quadrivalent Inactivated Influenza Vaccine (QIS) versus Fluarix Tetra Vaccine in Healthy Subjects.

X
Trial Profile

A Phase III, Multi-center, Single-dose, Randomized, Double-blind, Non-inferiority and Lot-to-lot Consistency Study of Immunogenicity and Safety Evaluation of AdimFlu-S Quadrivalent Inactivated Influenza Vaccine (QIS) versus Fluarix Tetra Vaccine in Healthy Subjects.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 07 Dec 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Quadrivalent inactivated influenza vaccine Adimmune Corporation (Primary) ; GSK 2321138A
  • Indications Influenza virus infections
  • Focus Therapeutic Use
  • Sponsors Adimmune Corporation
  • Most Recent Events

    • 10 May 2017 Status changed from recruiting to completed, according to an Adimmune Corporation media release.
    • 23 Nov 2016 According to an Adimmune Corporation media release, company begin the process for a Biologics License Application (BLA) in 2017.
    • 09 Nov 2016 New trial record
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top